Seeking Alpha

Ariad slumps as Clovis finds no interest

  • Ariad Pharmaceuticals (ARIA -3.6%) began the day in the red and has traded steadily lower throughout the session.
  • Perhaps weighing on the shares is the news that Clovis Oncology (CLVS -11.1%) has received no interest from buyers after hiring Credit Suisse to explore strategic options.
  • Like CLVS' lead compound CO-1686, ARIA's AP26113 is an EGFR inhibitor.
  • When news hit last week that CLVS was pursuing a sale, ARIA spiked.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector